Effects of HMG-coA Reductase Pathway Inhibitors on GCAD
HMG-coA 还原酶途径抑制剂对 GCAD 的影响
基本信息
- 批准号:7158362
- 负责人:
- 金额:$ 5.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-22 至 2008-09-21
- 项目状态:已结题
- 来源:
- 关键词:G proteinHMG coA reductasesalkyltransferaseatorvastatinbioluminescencecardiovascular disorder preventionchemopreventioncoronary disordergeranyl compoundgreen fluorescent proteinsheart transplantationimmunopharmacologylaboratory mousemicroarray technologymorphometryoxidoreductase inhibitorpostdoctoral investigatorsqualenetransplant rejection
项目摘要
DESCRIPTION (provided by applicant): Chronic rejection is the leading cause of death in heart transplant patients, yet, no effective treatment exists. One therapy that has shown promise is the use of HMG-CoA reductase inhibitors (statins), but the mechanism by which they operate remains unclear. This proposal describes a research project designed to delineate the role of HMG-CoA reductase pathway inhibitors in the prevention of chronic rejection in a murine cardiac transplant model. In addition, this project will lead to a greater understanding of the pathways affected in the formation of chronic rejection. This will be done by employing a novel model of chronic rejection which relies on bioluminescence imaging. The project has four specific aims: (1) the development and validation of the FVB Luciferase-GFP (beta-actin) to C57BL/6 cardiac transplant model of chronic rejection; (2) determination of the ability of atorvastatin to decrease the degree of chronic rejection in the model; (3) analysis of the ability of specific HMG-CoA reductase pathway inhibitors to suppress chronic rejection in this model; and (4) examination of the intracellular pathways affected by inhibition of the HMG- CoA reductase pathway using gene microarrays.
描述(由申请人提供):慢性排斥反应是心脏移植患者死亡的主要原因,目前尚无有效的治疗方法。一种有希望的治疗方法是使用HMG-CoA还原酶抑制剂(他汀类药物),但其作用机制尚不清楚。该提案描述了一个研究项目,旨在描述HMG-CoA还原酶途径抑制剂在小鼠心脏移植模型中预防慢性排斥反应中的作用。此外,该项目将导致对慢性排斥形成的途径有更深入的了解。这将通过采用一种依赖于生物发光成像的新型慢性排斥模型来完成。该项目有四个具体目标:(1)开发和验证FVB荧光素- gfp (β -actin)对C57BL/6心脏移植慢性排斥模型的影响;(2)测定阿托伐他汀降低模型慢性排斥程度的能力;(3)分析HMG-CoA还原酶途径特异性抑制剂抑制慢性排斥反应的能力;(4)利用基因芯片检测受HMG- CoA还原酶途径抑制影响的细胞内通路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM STEIN其他文献
WILLIAM STEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM STEIN', 18)}}的其他基金
Effects of HMG-coA Reductase Pathway Inhibitors on GCAD
HMG-coA 还原酶途径抑制剂对 GCAD 的影响
- 批准号:
7346990 - 财政年份:2006
- 资助金额:
$ 5.14万 - 项目类别:
相似海外基金
Scaffolds for Synthesis of Probes Directed Against Class II HMG-CoA Reductases
用于合成针对 II 类 HMG-CoA 还原酶的探针的支架
- 批准号:
7367432 - 财政年份:2007
- 资助金额:
$ 5.14万 - 项目类别:














{{item.name}}会员




